CAPRIN-1 Targeting Composition for Tumorigenesis Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments lack effective methods to suppress the expression of the CAPRIN-1 protein on the membrane surface of cancer cells, which is crucial for tumorigenesis.
Innovation Solution
A pharmaceutical composition comprising substances that reduce the expression of CAPRIN-1 protein on cancer cell membranes, including AMPK inhibitors, Wnt agonists, Akt/PI3K inhibitors, P53 inhibitors, Rac1 inhibitors, ROS generating factors, ErbB2/HER2 inhibitors, GSK3β inhibitors, endocytosis inhibitors, Wnt/β-catenin inhibitors, nucleic acid molecules, enzymes like trypsin or chymotrypsin, and antibodies that bind to CAPRIN-1 protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If molecular targeting drugs (antibodies, small molecules, nucleic acids) are used to suppress protein expression in cancer cells, then target specificity is improved, but the ability to specifically reduce CAPRIN-1 protein on the membrane surface remains insufficient
Solution Approach 1:
The patent employs multiple substances (AMPK inhibitors, Wnt agonists, Akt/PI3K inhibitors, P53 inhibitors, Rac1 inhibitors, ROS generating factors, ErbB2/HER2 inhibitors, GSK3β inhibitors, endocytosis inhibitors, Wnt/β-catenin inhibitors, nucleic acid molecules, and enzymes) that work through different molecular mechanisms to reduce CAPRIN-1 protein expression on the membrane surface, thereby achieving reliable suppression through multiple pathways
Solution Approach 2:
The patent combines multiple types of molecular targeting agents (antibodies, small molecules, nucleic acids, enzymes) into a comprehensive therapeutic approach, utilizing their complementary mechanisms to achieve both high specificity and reliable reduction of CAPRIN-1 expression
2Reliability
If CAPRIN-1 protein is targeted on cancer cell membranes, then tumorigenesis suppression is improved, but the complexity of delivering substances to the membrane surface increases
Solution Approach 1:
The patent focuses specifically on reducing CAPRIN-1 protein on the membrane surface rather than targeting intracellular processes, thereby simplifying the delivery requirement to extracellular access while achieving tumorigenesis suppression
Solution Approach 2:
The patent uses various substances including antibodies, enzymes (trypsin, chymotrypsin), and small molecule inhibitors as intermediaries that can access the membrane surface and reduce CAPRIN-1 expression, serving as mediators between the therapeutic agent and the target protein
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The reduction of CAPRIN-1 protein expression suppresses tumorigenesis in cancer patients, demonstrated by decreased anchorage-independent colony-forming ability and tumorigenicity in vivo.
Implementation Method 1
the nucleic acid molecule is at least one nucleic acid molecule selected from the group consisting of a small interfering RNA (siRNA), a micro RNA, a small hairpin RNA (shRNA), a guide RNA (gRNA), an antisense nucleic acid, a ribozyme and a nucleic acid aptamer, targeting the CAPRIN-1 gene
Implementation Method 2
the substance is an enzyme that degrades the CAPRIN-1 protein on the membrane surface of the cancer cell. (8) The pharmaceutical composition according to (8), wherein the enzyme is trypsin or chymotrypsin
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
A substance that reduces an expression of a CAPRIN-1 protein on a membrane surface of a cancer cell, specifically a substance that reduces an expression level of the CAPRIN-1 protein on the membrane surface of the cancer cell, or a substance that binds to the CAPRIN-1 protein on the membrane surface of the cancer cell can be used as an active ingredient of a pharmaceutical composition for treating and/or preventing a cancer.